Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)

Keros Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$481.8 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings rose 15.3% year-over-year to -$481.8 million; the trailing twelve-month figure through Dec 2025 stood at -$481.8 million (up 15.3% YoY), and the FY2025 full-year result was -$481.8 million, up 15.3% from the prior year.
• Retained Earnings for Q4 2025 stood at -$481.8 million, down from -$458.3 million in the prior quarter.
• The five-year high for Retained Earnings was -$80.9 million in Q1 2021, with the low at -$568.8 million in Q4 2024.
• Historically, Retained Earnings has averaged -$312.7 million across 5 years, with a median of -$321.5 million in 2023.
• Annual changes were most pronounced in 2021 — Retained Earnings slumped 156.47% — and 2025, when it gained 15.3%.
• Keros Therapeutics' Retained Earnings stood at -$123.8 million in 2021, then slumped by 84.59% to -$228.4 million in 2022, then tumbled by 66.97% to -$381.4 million in 2023, then slumped by 49.12% to -$568.8 million in 2024, then increased by 15.3% to -$481.8 million in 2025.
• The last three Retained Earnings figures came in at -$481.8 million (Q4 2025), -$458.3 million (Q3 2025), and -$451.0 million (Q2 2025), per Business Quant data.